

Archerfish Precision Diagnostics and C2N Diagnostics collaborate to provide advanced Alzheimer's diagnostics in Singapore and Asia

24 July 2025 | News

New Microsoft Research Asia lab in Singapore to drive fundamental research and talent development in collaboration with local institutions



Archerfish Precision Diagnostics (Archerfish), a premier diagnostic laboratory serving Singapore and the broader Asian region and C2N Diagnostics, LLC (C2N), a leader in advanced brain health Diagnostics, today announced a strategic partnership to introduce and expand access to C2N's innovative blood-based diagnostic test for Alzheimer's Disease (AD). This collaboration marks a significant step forward in improving early and accurate diagnosis of AD, a critical need across Asia.

The partnership will leverage Archerfish extensive network and expertise in laboratory services and patient outreach throughout Singapore and other key Asian markets. This will facilitate the widespread availability of C2N's cutting-edge PrecivityAD2™ blood test, which offers a less invasive and more accessible method for detecting amyloid pathology in the brain, a hallmark of AD, all through a single blood draw.

Embracing breakthrough technology in Alzheimer's Disease diagnostics

This innovative diagnostic test is the first of its kind in Singapore and signals a step towards more accessible, non-invasive AD Diagnostics. The PrecivityAD2™ blood test is intended for individuals 55 and older who are being evaluated by a healthcare provider for AD or other causes of cognitive decline. Using high resolution liquid chromatography, tandem mass spectrometry, PrecivityAD2™ detects specific amyloid beta and tau peptides circulating in blood that are associated with the presence of amyloid plaques in the brain that can aid healthcare providers in the diagnosis of AD.

Early and accurate diagnosis of AD is paramount for several reasons: it allows patients and their families to plan for the future, access appropriate care and support services, and potentially enrol in clinical trials for emerging therapies. Traditional diagnostic methods can be invasive, costly, and open inaccessible in many regions. C2N's PrecivityAD2™ blood test aims to overcome these barriers, providing a more convenient and scalable solution.

Addressing Alzheimer's Disease in Singapore's Ageing population

In light of a rapidly ageing population, this partnership seeks to strengthen local capabilities for AD diagnosis. Given that the risk of dementia increases with age, Singapore will likely see a rise in the number of cases as her population continues to age, highlighting the need for accessible yet highly accurate diagnostic tools such as PrecivityAD2™. While cognitive issues may have many potential causes, the PrecivityAD2™ blood test can provide greater clarity in an AD diagnosis. The PrecivityAD2™ test result is a clinically validated algorithm that can either confirm the presence of amyloid pathology and increase confidence in an AD diagnosis to enable patients to take more action to manage their condition or rule out AD as a cause for cognitive decline, thus avoiding additional rounds of testing and accelerating a timely intervention. In either case, PrecivityAD2™ empowers healthcare providers and patients to improve healthcare outcomes through increased diagnostic certainty.

"Accurate and accessible diagnosis is an important cornerstone in the management of Alzheimer's Disease. With advances in blood-based biomarkers, we are seeing new possibilities that complement standard diagnostic methods and support more timely clinical decision-making. Such developments hold promise for improving care for individuals experiencing cognitive decline," said Professor Christopher Chen, Director, Memory Aging and Cognition Centre, National University Health System.